Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

Exclusion Criteria

• •1. Have inadequate intravenous access
• •2. Patients with significant cognitive impairment
• •3. Active, clinically significant asthma
• •4. History of allergy or hypersensitivity to any component of intravenous ibuprofen, NSAIDs, aspirin (or related products), cyclooxygenase-2 inhibitors, or fentanyl.
• •5. Have a history of congenital bleeding diathesis (e.g. hemophilia) or any active clinically significant bleeding
• •6. Any child with obstructive sleep apnea, defined as an Apnea-Hypopnea Index of greater than or equal to 5.0
• •7. Have taken investigational drugs within 30 days before clinical trial material administration.
• •8. Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board \[IRB\]) and agree to abide by the study restrictions. Surrogates will be needed for most patients.
• •9. Refusal to provide written authorization for use and disclosure of protected health information.
• •10. Be otherwise unsuitable for the study, in the opinion of the Investigator.